毒理性
在临床试验中，鲁比前列酮治疗并未与血清酶水平的显著变化或临床上明显的肝脏损伤事件相关联。自从其获得批准和上市以来，已经有一些孤立病例报告血清转氨酶升高，但尚未有公开发表的报道称鲁比前列酮导致了临床上明显的肝脏损伤。因此，如果鲁比前列酮确实导致肝脏损伤，这种情况也极为罕见。
In clinical trials, lubiprostone therapy was not associated with significant changes in serum enzyme levels or episodes of clinically apparent liver injury. Since its approval and marketing, isolated case reports of serum aminotransferase elevations have been reported to the sponsor, but there have been no published reports of clinically apparent liver injury attributable to lubiprostone. Thus, liver injury from lubiprostone must be extremely rare, if it occurs at all.
来源:LiverTox
